Statin Regulation of CYP3A4 and CYP3A5 Expression

• Brown CM , ReisfeldB, MayenoAN: Cytochromes P450: a structure-based summary of biotransformations using representative substrates.Drug Metab. Rev.40(1) , 1–100 (2008).
   PubMed Web of Science ®Google Scholar
• Zanger UM , TurpeinenM, KleinK, SchwabM: Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation.Anal. Bioanal. Chem.392(6) , 1093–1108 (2008).
   PubMed Web of Science ®Google Scholar
• Wang K , ChenS, XieW, WanYJ: Retinoids induce cytochrome P450 3A4 through RXR/VDR-mediated pathway.Biochem. Pharmacol.75(11) , 2204–2213 (2008).
   PubMed Web of Science ®Google Scholar
• Kuehl P , ZhangJ, LinY et al.: Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression.Nat. Genet.27 , 383–391 (2001).
   PubMed Web of Science ®Google Scholar
• Koch I , WeilR, WolboldR et al.: Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA.Drug Metab. Dispos.30(10) , 1108–1114 (2002).
   PubMed Web of Science ®Google Scholar
• Lin YS , DowlingLS, QuigleySD et al.: Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism.Mol. Pharmacol.62(1) , 162–171 (2002).
   PubMed Web of Science ®Google Scholar
• Hesselink DA , van Schaik RH, van der Heiden IP et al.: Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the MDR-1, CYP3A4, and CYP3A5 genes. Clin. Pharmacol. Ther.76(6) , 545–556 (2004).
   PubMed Web of Science ®Google Scholar
• Anglicheau D , LegendreC, BeauneP, ThervetE: Cytochrome P450 3A polymorphisms and immunosuppressive drugs: an update.Pharmacogenomics8(7) , 835–849 (2007).
   PubMed Web of Science ®Google Scholar
• Jin Y , WangYH, MiaoJ et al.: Cytochrome P450 3A5 genotype is associated with verapamil response in healthy subjects.Clin. Pharmacol. Ther.82(5) , 579–585 (2007).
   PubMed Web of Science ®Google Scholar
• Josephson F , AllqvistA, JanabiM et al.: CYP3A5 genotype has an impact on the metabolism of the HIV protease inhibitor saquinavir.Clin. Pharmacol. Ther.81(5) , 708–712 (2007).
   PubMed Web of Science ®Google Scholar
• Cavalli SA , HirataMH, HirataRDC: Detection of MboII polymorphism at the 5´promoter region of CYP3A4.Clin. Chem.47(2) , 348–351 (2001).
   PubMed Web of Science ®Google Scholar
• Fiegenbaum M , da Silveira FR, Van der Sand CR et al.: The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment. Clin. Pharmacol. Ther.78 , 551–558 (2005).
   PubMed Web of Science ®Google Scholar
• Cavalli SA , RebecchiIMM, MatsumotoLO et al.: Lowering cholesterol response to atorvastatin is not influenced by CYP3A4*1B.Biofarma3(6) , 29–35 (2008).
   Google Scholar
• Suarez-Kurtz G , PeriniJA, Bastos-RodriguesL, PenaSD, StruchinerC: Impact of population admixture on the distribution of the CYP3A5*3 polymorphism.Pharmacogenomics8(10) , 1299–1306 (2007).
   PubMed Web of Science ®Google Scholar
• Willrich MAV , HirataMH, GenvigirFD et al.: CYP3A5*3A allele is associated with reduced lowering-lipid response to atorvastatin in individuals with hypercholesterolemia.Clin. Chim. Acta398(1–2) , 15–20 (2008).
   PubMed Web of Science ®Google Scholar
• Vaughan CJ , GottoAM Jr: Update on statins: 2003. Circulation110 , 886–892 (2004).
   PubMed Web of Science ®Google Scholar
• Liao JK , LaufsU: Pleiotropic effects of statins.Annu. Rev. Pharmacol. Toxicol.45 , 89–118 (2005).
   PubMed Web of Science ®Google Scholar
• Danesh FR , KanwarYS: Modulatory effects of HMG-coA reductase inhibitors in diabetic microangiopathy.FASEB J.18 , 905–915 (2004).
   PubMed Web of Science ®Google Scholar
• Neuvonen PJ , NiemiM, BackmanJT: Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance.Clin. Pharmacol. Ther.80(6) , 565–581 (2006).
   PubMed Web of Science ®Google Scholar
• Park JE , KimKB, BaeSK, MoonBS, LiuKH, ShinJG: Contribution of cytochrome P450 3A4 and 3A5 to the metabolism of atorvastatin.Xenobiotica38(9) , 1240–1251 (2008).
   PubMed Web of Science ®Google Scholar
• Mangravite LM , ThornCN, KraussRM: Clinical implications of pharmacogenomics of statin treatment.Pharmacogenomics J.6(6) , 360–374 (2006).
   PubMed Web of Science ®Google Scholar
• Grube M , KöckK, OswaldS et al.: Organic anion transporter polypeptide 2B1 is a high-affinity transporter for atorvastatin and is expressed in the human heart.Clin. Pharmacol. Ther.80(6) , 607–620 (2006).
   PubMed Web of Science ®Google Scholar
• Rodrigues AC , HirataMH, HirataRDC: The genetic determinants of atorvastatin response.Curr. Opin. Mol. Ther.9(6) , 545–553 (2007).
   PubMedGoogle Scholar
• Kim KA , ParkPW, LeeOJ, KangBS: Effect of polymorphic CYP3A5 genotype on the single-dose simvastatin pharmacokinetics in healthy subjects.J. Clin. Pharmacol.47 , 87–93 (2007).
   PubMed Web of Science ®Google Scholar
• Salazar LA , CavalliSA, HirataMH et al.: Polymorphisms of the low-density lipoprotein receptor gene in Brazilian individuals with heterozygous familial hypercholesterolemia.Braz. J. Med. Biol. Res.33(11) , 1301–1304 (2000).
   PubMed Web of Science ®Google Scholar
• Guzmán EC , HirataMH, QuintãoEC, HirataRDC: Association of the apolipoprotein B gene polymorphisms with cholesterol levels and response to fluvastatin in Brazilian individuals with high-risk for coronary heart disease.Clin. Chem. Lab. Med.38(8) , 731–736 (2000).
   PubMed Web of Science ®Google Scholar
• Sorkin SC , ForestieroFJ, HirataMH et al.: APOA1 polymorphisms are associated with variations in serum triglyceride concentrations in hypercholesterolemic individuals.Clin. Chem. Lab. Med.43 , 1339–1345 (2005).
   PubMed Web of Science ®Google Scholar
• Arazi SS , GenvigirFD, WillrichMA et al.: Atorvastatin effects on SREBF1a and SCAP gene expression in mononuclear cells and its relation with lowering-lipids response.Clin. Chim. Acta393(2) , 119–124 (2008).
   PubMed Web of Science ®Google Scholar
• Genvigir FD , SoaresSA, HirataMH et al.: Effects of ABCA1 SNPs, including the C-105T novel variant, on serum lipids of Brazilian individuals.Clin. Chim. Acta389 , 79–86 (2008).
   PubMed Web of Science ®Google Scholar
• Kajinami K , BrousseauME, OrdovasJM, SchaeferEJ:CYP3A4genotypes and plasma lipoprotein levels before and treatment with atorvastatin in primary hypercholesterolemia. Am. J. Cardiol.93 , 104–107 (2004).
   PubMed Web of Science ®Google Scholar
• Chasman DI , PosadaD, SubrahmanyanL, CookNR, StantonVP Jr, Ridker PM: Pharmacogenetic study of statin therapy and cholesterol reduction. JAMA291(23) , 2821–2827 (2004).
   PubMed Web of Science ®Google Scholar
• Schuetz EG : Lesson from the CYP3A4 promoter.Mol. Pharmacol.65(2) , 279–281 (2004).
   PubMed Web of Science ®Google Scholar
• Kivisto KT , NiemiM, SchaeffelerE et al.: Lipid-lowering response to statins is affected by CYP3A5 polymorphism.Pharmacogenetics14 , 523–525 (2004).
   PubMedGoogle Scholar
• Bellosta S , PaolettiR, CorsiniA: Safety of statins: focus on clinical pharmacokinetics and drug interactions.Circulation109(23 Suppl. 1) , III50–III57 (2004).
   PubMed Web of Science ®Google Scholar
• Conforti A , ChiamuleraC, MorettiU, ColceraS, FumagalliG, LeoneR: Musculoskeletal adverse drug reactions: a review of literature and data from ADR spontaneous reporting databases.Curr. Drug Saf.2(1) , 47–63 (2007).
   PubMedGoogle Scholar
• Wilke RA , MooreJH, BurmesterJK: Relative impact of CYP3A genotype and concomitant medication on the severity of atorvastatin-induced muscle damage.Pharmacogenet. Genomics15 , 415–421 (2005).
   PubMed Web of Science ®Google Scholar
• Corsini A : The safety of HMG-CoA reductase inhibitors in special populations at high cardiovascular risk.Cardiovasc. Drugs Ther.17(3) , 265–285 (2003).
   PubMed Web of Science ®Google Scholar
• Kocarek TA , DahnMS, CaiH, StromSC, Mercer-HainesNA: Regulation of CYP2B6 and CYP3A expression by hydroxymethylglutaryl coenzyme A inhibitors in primary cultured human hepatocytes.Drug Metab. Dispos.30(12) , 1400–1405 (2002).
   PubMed Web of Science ®Google Scholar
• Watanabe M , KumaiT, MatsumotoN et al.: Expression of CYP3A4 mRNA is correlated with CYP3A4 protein level and metabolic activity in human liver.J. Pharmacol. Sci.94 , 459–462 (2004).
   PubMed Web of Science ®Google Scholar
• Takagi S , NakajimaM, MohriT, YokoiT: Post-transcriptional regulation of human pregnane X receptor by micro-RNA affects the expression of cytochrome P450 3A4.J. Biol. Chem.283(15) , 9674–9680 (2008).
   PubMed Web of Science ®Google Scholar
• Willrich MAV , HirataMH, RodriguesAC et al.: CYP3A4 and CYP3A5 mRNA expression are affected by atorvastatin in HepG2 cell line. Fourth Santorini Conference Biologie Prospective 2008, Santorini, Greece, Sep 21–23, 2008.Clin. Chem. Lab. Med.46(8) , A143 (2008).
   PubMedGoogle Scholar
• Christians U , SchmitzV, HasckeM: Functional interactions between P-glycoprotein and CYP3A in drug metabolism.Expert Opin. Drug Metab. Toxicol.1(4) , 641–654 (2005).
   PubMedGoogle Scholar
• Lehmann JM , McKeeDD, WatsonMA, WilsonTM, MooreJT, KliewerSA: The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions.J. Clin. Invest.102(5) , 1016–1023 (1998).
   PubMed Web of Science ®Google Scholar
• Wagner M , HalilbasicE, MarschallHU et al.: CAR and PXR agonists stimulate hepatic bile acid and bilirubin detoxification and elimination pathways in mice.Hepatology42(2) , 420–430 (2005).
   PubMed Web of Science ®Google Scholar
• Kobayashi K , YamanakaY, IwazakiN et al.: Identification of HMG-CoA reductase inhibitors as activators for human, mouse and rat constitutive androstane receptor.Drug Metab. Dispos.33(7) , 924–929 (2005).
   PubMed Web of Science ®Google Scholar
• Goodwin B , HodgsonE, D‘CostaDJ, RobertsonGR, LiddleC: Transcriptional regulation of the human CYP3A4 gene by the constitutive androstane receptor.Mol. Pharmacol.62(2) , 359–365 (2002).
   PubMed Web of Science ®Google Scholar
• Goodwin B , HodgsonE, LiddleC: The orphan human pregnane X receptor mediates the transcriptional activation of CYP3A4 by rifampicin through a distal enhancer module.Mol. Pharmacol.56(6) , 1329–1339 (1999).
   PubMed Web of Science ®Google Scholar
• Martin P , RileyR, BackDJ, OwenA: Comparison of the induction profile for drug disposition by typical nuclear receptor activators in human hepatic and intestinal cells.Br. J. Pharmacol.153(4) , 805–819 (2008).
   PubMed Web of Science ®Google Scholar
• Xie HG , WoodAJ, KimRB, SteinCM, WilkinsonGR: Genetic variability in CYP3A5 and its possible consequences.Pharmacogenomics5 , 243–272 (2004).
   PubMed Web of Science ®Google Scholar
• Burk O , WojnowskiL: Cytochrome P450 3A and their regulation.Naunyn Schmiedebergs Arch. Pharmacol.369 , 105–124 (2004).
   PubMed Web of Science ®Google Scholar
• Krusekopt S , RootsI, KleeberU: Differential drug-induced mRNA expression of human CYP3A4 compared with CYP3A5, CYP3A7 and CYP3A43.Eur. J. Pharmacol.466(1–2) , 7–12 (2003).
   PubMed Web of Science ®Google Scholar

▪ Websites

• Human cytochrome P450 (CYP) allele nomenclature committee www.cypalleles.ki.se/
   Google Scholar
• SNP database (dbSNP) from NCBI www.ncbi.nlm.nih.gov/SNP
   Google Scholar